CMS Skeptical Of Watchman, CardioMEMS Data For New-Tech Add-Ons

The Medicare agency is questioning whether Boston Scientific’s Watchman stroke device or the CardioMEMS implantable heart failure monitor, championed by St. Jude Medical, can meet the “substantial clinical improvement” threshold to qualify for an inpatient new-technology add-on payment.